File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Altered expression and deletion of RMO1 in osteosarcoma
  • Basic View
  • Metadata View
  • XML View
TitleAltered expression and deletion of RMO1 in osteosarcoma
 
AuthorsEppert, K4 3
Wunder, JS4 3 2
Aneliunas, V4
Tsui, LC5 3 1
Scherer, SW5 3
Andrulis, IL2 4 3
 
KeywordsLoss of heterozygosity
Metastasis
mRNA expression
Osteosarcoma
RMO1
 
Issue Date2005
 
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
CitationInternational Journal Of Cancer, 2005, v. 114 n. 5, p. 738-746 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.20786
 
AbstractIn order to increase our understanding of the molecular events underlying osteosarcoma progression, the expression of approximately 950 genes was examined in 24 primary and metastatic osteosarcoma tumor specimens. A gene, RMO1, was isolated with decreased expression in metastatic samples. Real-Time PCR corroborated this pattern, revealing lower expression in the primary sample in 6 of 7 cases for which both primary and metastatic osteosarcoma samples were available from the same patient (p = 0.034). RMO1 is located at 2q33, a region of frequent loss of heterozygosity in cancer, and exhibited loss of heterozygosity in 6 out of 9 primary osteosarcoma tumor samples (67%). Loss of heterozygosity is evident in primary tumors while the decrease in gene expression is seen in the metastatic samples, indicating that these 2 events are separately implicated in cancer progression. Cloning of RMO1 revealed an open reading frame with multiple splice forms with significant homology to GRB7, 10 and 14 and MIG10 in the region containing a Pleckstrin homology domain and a Ras association domain, suggestive of a role in cell signaling and migration. Northern blot analysis indicated that RMO1 mRNA is ubiquitously expressed in tissues except for peripheral blood leukocytes. These data suggest that RMO1 may be a candidate for a protein involved in inhibiting tumor progression. © 2004 Wiley-Liss, Inc.
 
ISSN0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
DOIhttp://dx.doi.org/10.1002/ijc.20786
 
ISI Accession Number IDWOS:000227535600008
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorEppert, K
 
dc.contributor.authorWunder, JS
 
dc.contributor.authorAneliunas, V
 
dc.contributor.authorTsui, LC
 
dc.contributor.authorScherer, SW
 
dc.contributor.authorAndrulis, IL
 
dc.date.accessioned2007-09-12T03:52:38Z
 
dc.date.available2007-09-12T03:52:38Z
 
dc.date.issued2005
 
dc.description.abstractIn order to increase our understanding of the molecular events underlying osteosarcoma progression, the expression of approximately 950 genes was examined in 24 primary and metastatic osteosarcoma tumor specimens. A gene, RMO1, was isolated with decreased expression in metastatic samples. Real-Time PCR corroborated this pattern, revealing lower expression in the primary sample in 6 of 7 cases for which both primary and metastatic osteosarcoma samples were available from the same patient (p = 0.034). RMO1 is located at 2q33, a region of frequent loss of heterozygosity in cancer, and exhibited loss of heterozygosity in 6 out of 9 primary osteosarcoma tumor samples (67%). Loss of heterozygosity is evident in primary tumors while the decrease in gene expression is seen in the metastatic samples, indicating that these 2 events are separately implicated in cancer progression. Cloning of RMO1 revealed an open reading frame with multiple splice forms with significant homology to GRB7, 10 and 14 and MIG10 in the region containing a Pleckstrin homology domain and a Ras association domain, suggestive of a role in cell signaling and migration. Northern blot analysis indicated that RMO1 mRNA is ubiquitously expressed in tissues except for peripheral blood leukocytes. These data suggest that RMO1 may be a candidate for a protein involved in inhibiting tumor progression. © 2004 Wiley-Liss, Inc.
 
dc.description.natureabstract
 
dc.identifier.citationInternational Journal Of Cancer, 2005, v. 114 n. 5, p. 738-746 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.20786
 
dc.identifier.doihttp://dx.doi.org/10.1002/ijc.20786
 
dc.identifier.epage746
 
dc.identifier.isiWOS:000227535600008
 
dc.identifier.issn0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
dc.identifier.issue5
 
dc.identifier.openurl
 
dc.identifier.pmid15609301
 
dc.identifier.scopuseid_2-s2.0-14844311294
 
dc.identifier.spage738
 
dc.identifier.urihttp://hdl.handle.net/10722/44391
 
dc.identifier.volume114
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshMedical sciences - oncology
 
dc.subject.meshMetastasis
 
dc.subject.meshRmo1
 
dc.subject.meshMrna expression
 
dc.subject.meshLoss of heterozygosity
 
dc.subjectLoss of heterozygosity
 
dc.subjectMetastasis
 
dc.subjectmRNA expression
 
dc.subjectOsteosarcoma
 
dc.subjectRMO1
 
dc.titleAltered expression and deletion of RMO1 in osteosarcoma
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Eppert, K</contributor.author>
<contributor.author>Wunder, JS</contributor.author>
<contributor.author>Aneliunas, V</contributor.author>
<contributor.author>Tsui, LC</contributor.author>
<contributor.author>Scherer, SW</contributor.author>
<contributor.author>Andrulis, IL</contributor.author>
<date.accessioned>2007-09-12T03:52:38Z</date.accessioned>
<date.available>2007-09-12T03:52:38Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>International Journal Of Cancer, 2005, v. 114 n. 5, p. 738-746</identifier.citation>
<identifier.issn>0020-7136</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/44391</identifier.uri>
<description.abstract>In order to increase our understanding of the molecular events underlying osteosarcoma progression, the expression of approximately 950 genes was examined in 24 primary and metastatic osteosarcoma tumor specimens. A gene, RMO1, was isolated with decreased expression in metastatic samples. Real-Time PCR corroborated this pattern, revealing lower expression in the primary sample in 6 of 7 cases for which both primary and metastatic osteosarcoma samples were available from the same patient (p = 0.034). RMO1 is located at 2q33, a region of frequent loss of heterozygosity in cancer, and exhibited loss of heterozygosity in 6 out of 9 primary osteosarcoma tumor samples (67%). Loss of heterozygosity is evident in primary tumors while the decrease in gene expression is seen in the metastatic samples, indicating that these 2 events are separately implicated in cancer progression. Cloning of RMO1 revealed an open reading frame with multiple splice forms with significant homology to GRB7, 10 and 14 and MIG10 in the region containing a Pleckstrin homology domain and a Ras association domain, suggestive of a role in cell signaling and migration. Northern blot analysis indicated that RMO1 mRNA is ubiquitously expressed in tissues except for peripheral blood leukocytes. These data suggest that RMO1 may be a candidate for a protein involved in inhibiting tumor progression. &#169; 2004 Wiley-Liss, Inc.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc.. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/journal/29331/home</publisher>
<relation.ispartof>International Journal of Cancer</relation.ispartof>
<subject>Loss of heterozygosity</subject>
<subject>Metastasis</subject>
<subject>mRNA expression</subject>
<subject>Osteosarcoma</subject>
<subject>RMO1</subject>
<subject.mesh>Medical sciences - oncology</subject.mesh>
<subject.mesh>Metastasis</subject.mesh>
<subject.mesh>Rmo1</subject.mesh>
<subject.mesh>Mrna expression</subject.mesh>
<subject.mesh>Loss of heterozygosity</subject.mesh>
<title>Altered expression and deletion of RMO1 in osteosarcoma</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0020-7136&amp;volume=114&amp;issue=5&amp;spage=738&amp;epage=746&amp;date=2005&amp;atitle=Altered+expression+and+deletion+of+RMO1+in+osteosarcoma</identifier.openurl>
<description.nature>abstract</description.nature>
<identifier.doi>10.1002/ijc.20786</identifier.doi>
<identifier.pmid>15609301</identifier.pmid>
<identifier.scopus>eid_2-s2.0-14844311294</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-14844311294&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>114</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>738</identifier.spage>
<identifier.epage>746</identifier.epage>
<identifier.isi>WOS:000227535600008</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Mount Sinai Hospital, Toronto
  3. University of Toronto
  4. Samuel Lunenfeld Research Institute
  5. Hospital for Sick Children University of Toronto